RT Journal Article
T1 Gender Differences in the Presentation and Outcomes of Hospitalized Patients With COVID-19.
A1 Biolè, Carloalberto
A1 Bianco, Matteo
A1 Núñez-Gil, Iván J
A1 Cerrato, Enrico
A1 Spirito, Amanda
A1 Roubin, Sergio Raposeiras
A1 Viana-Llamas, María C
A1 Gonzalez, Adelina
A1 Castro-Mejía, Alex F
A1 Eid, Charbel Maroun
A1 Fernández-Pérez, Cristina
A1 Uribarri, Aitor
A1 Alfonso-Rodriguez, Emilio
A1 Ugo, Fabrizio
A1 Guerra, Federico
A1 Feltes, Gisela
A1 Akin, Ibrahim
A1 Fernández-Rozas, Inmaculada
A1 Blasco-Angulo, Natividad
A1 Huang, Jia
A1 Aguado, Marcos Garcia
A1 Pepe, Martino
A1 Romero, Rodolfo
A1 Becerra-Muñoz, Víctor Manuel
A1 Estrada, Vicente
A1 Macaya, Carlos
AB Gender-related differences in COVID-19 clinical presentation, disease progression, and mortality have not been adequately explored. We analyzed the clinical profile, presentation, treatments, and outcomes of patients according to gender in the HOPE-COVID-19 International Registry. Among 2,798 enrolled patients, 1,111 were women (39.7%). Male patients had a higher prevalence of cardiovascular risk factors and more comorbidities at baseline. After propensity score matching, 876 men and 876 women were selected. Male patients more often reported fever, whereas female patients more often reported vomiting, diarrhea, and hyposmia/anosmia. Laboratory tests in men presented alterations consistent with a more severe COVID-19 infection (eg, significantly higher C-reactive protein, troponin, transaminases, lymphocytopenia, thrombocytopenia, and ferritin). Systemic inflammatory response syndrome, bilateral pneumonia, respiratory insufficiency, and renal failure were significantly more frequent in men. Men more often required pronation, corticosteroids, and tocilizumab administration. A significantly higher 30-day mortality was observed in men vs women (23.4% vs 19.2%; P = .039). Trial Numbers: NCT04334291/EUPAS34399.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/18000
UL http://hdl.handle.net/10668/18000
LA en
DS RISalud
RD Apr 6, 2025